The bsAb Amivantamab targeting mesenchymal transition factor (MET) and epidermal growth factor receptor (EGFR) was developed using this platform for the treatment of advanced non-small cell lung cancer. This evidence concerns the gene EGFR and non-small cell lung carcinoma.